Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?
Sulfonylureas (SUs) are commonly used as add-on to metformin in treatment of type 2 diabetes in patients who are insufficiently controlled by metformin alone. They have good efficacy and have been shown to prevent microvascular complications. However, treatment with SUs is also associated with a high frequency of hypoglycemia, increased body weight, and a high risk of secondary failure. During recent years, dipeptidyl peptidase-4 (DPP-4) inhibitors have emerged as alternatives to SUs. They show similar efficacy as SUs but with lower risk of hypoglycemia, and reduction or no change in body weight, and if confirmed in humans, they may preserve islet function and thereby minimize the risk for secondary failure. Their limitation at present is the lack of long-term (>5 years) experience on durability and safety. Overall, therefore, the conclusion emerges that SUs are less desirable than DPP-4 inhibitors in management of hyperglycemia in type 2 diabetes.
Department of Clinical Sciences Lund, Lund University, B11 BMC, SE-221 84, Lund, Sweden. Bo.Ahren@med.lu.se
Bo
B
Ahrén
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008687:Metformin / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D016896:Treatment Outcome
D054873:Dipeptidyl-Peptidase IV Inhibitors; D013453:Sulfonylurea Compounds; D008687:Metformin
J Diabetes Complications. 1994 Oct-Dec;8(4):201-3
7833494
Diabetes Care. 1984 May-Jun;7 Suppl 1:3-7
6376027
Lancet. 1998 Sep 12;352(9131):837-53
9742976
Diabetes. 2006 Jun;55(6):1695-704
16731832
Diabetologia. 2005 Sep;48(9):1700-13
16132964
Drugs. 2010 Mar 5;70(4):489-512
20205490
Expert Opin Investig Drugs. 2010 Jan;19(1):133-40
19947894
N Engl J Med. 2008 Jun 12;358(24):2560-72
18539916
Diabetes Care. 2002 May;25(5):869-75
11978683
Drugs. 2004;64(12):1339-58
15200348
Diabet Med. 2010 Mar;27(3):318-26
20536495
Horm Metab Res. 2004 Nov-Dec;36(11-12):804-10
15655712
BMJ. 2009 May 22;338:b1668
19465464
Diabetologia. 2009 Jan;52(1):17-30
18941734
Diabetes Obes Metab. 2011 Feb;13(2):160-8
21199268
Nutr Metab Cardiovasc Dis. 2009 Nov;19(9):604-12
19427768
Int J Clin Pract. 2010 May;64(6):791-801
20518953
Diabetologia. 2010 Aug;53(8):1552-61
20407743
Expert Opin Investig Drugs. 2009 Oct;18(10):1495-503
19758106
Diabetes Obes Metab. 2010 Sep;12(9):780-9
20649630
Diabetes Obes Metab. 2007 Mar;9(2):194-205
17300595
J Clin Endocrinol Metab. 2004 Jan;89(1):297-302
14715864
J Histochem Cytochem. 2007 Aug;55(8):795-804
17438353
Diabetes. 2009 Mar;58(3):726-31
19095762
Diabetes Obes Metab. 2009 Feb;11(2):157-66
19125777
N Engl J Med. 2003 Jan 30;348(5):383-93
12556541
N Engl J Med. 1992 May 14;326(20):1316-22
1348845
N Engl J Med. 2008 Jun 12;358(24):2545-59
18539917
Expert Opin Investig Drugs. 2006 Apr;15(4):431-42
16548792
Diabetes Metab. 2008 Feb;34 Suppl 2:S56-64
18640587
Int J Clin Pract. 2010 Apr;64(5):562-76
20456211
Pflugers Arch. 1999 Sep;438(4):428-36
10519134
Diabetologia. 2003 Jul;46(7):875-91
12819907
Expert Opin Emerg Drugs. 2008 Dec;13(4):593-607
19046129
Lancet. 2006 Nov 11;368(9548):1696-705
17098089
Expert Opin Pharmacother. 2009 Feb;10(3):503-12
19191685
Diabet Med. 2006 Jun;23(6):579-93
16759299
Diabetes Care. 2010 Apr;33(4):730-2
20067974
Diabetes. 1970;19:Suppl:789-830
4926376
Nat Rev Drug Discov. 2009 May;8(5):369-85
19365392
Diabet Med. 2008 Mar;25(3):245-54
18215172
Int J Clin Pract. 2010 Nov;64(12):1619-31
20846286
J Clin Endocrinol Metab. 2009 Apr;94(4):1236-43
19174497
BMJ. 2009 Dec 03;339:b4731
19959591
Int J Clin Pract. 2004 Sep;58(9):833-7
15529516
Diabetologia. 2003 Jan;46(1):3-19
12637977
J Diabetes Complications. 2005 Jan-Feb;19(1):60-4
15642492
Adv Ther. 2009 May;26(5):488-99
19444391
Diabetes. 2003 Jan;52(1):102-10
12502499
Endocr Pract. 2009 Sep-Oct;15(6):540-59
19858063